JP2017520598A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017520598A5 JP2017520598A5 JP2017502119A JP2017502119A JP2017520598A5 JP 2017520598 A5 JP2017520598 A5 JP 2017520598A5 JP 2017502119 A JP2017502119 A JP 2017502119A JP 2017502119 A JP2017502119 A JP 2017502119A JP 2017520598 A5 JP2017520598 A5 JP 2017520598A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkylene
- substituted
- alkoxy
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 28
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 125000001424 substituent group Chemical group 0.000 claims 13
- 150000003230 pyrimidines Chemical class 0.000 claims 12
- -1 N- pyrrolidinyl Chemical group 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 9
- 229910052757 nitrogen Chemical group 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 4
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 239000011593 sulfur Chemical group 0.000 claims 3
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010001889 Alveolitis Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009137 Chronic sinusitis Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 206010056626 Pseudopolyp Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 1
- 206010037423 Pulmonary oedema Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000038016 acute inflammation Diseases 0.000 claims 1
- 230000006022 acute inflammation Effects 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 208000024207 chronic leukemia Diseases 0.000 claims 1
- 208000013507 chronic prostatitis Diseases 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 230000002518 glial effect Effects 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 208000020123 juvenile polyp Diseases 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000003843 mucus production Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 208000037916 non-allergic rhinitis Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000001797 obstructive sleep apnea Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 208000027232 peripheral nervous system disease Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 208000005333 pulmonary edema Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 210000001835 viscera Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14002450.6 | 2014-07-16 | ||
| EP14002450 | 2014-07-16 | ||
| PCT/EP2015/001473 WO2016008590A1 (en) | 2014-07-16 | 2015-07-16 | Novel 2,5-substituted pyrimidines as pde4 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017520598A JP2017520598A (ja) | 2017-07-27 |
| JP2017520598A5 true JP2017520598A5 (enExample) | 2018-02-01 |
| JP6723217B2 JP6723217B2 (ja) | 2020-07-15 |
Family
ID=51210959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017502119A Expired - Fee Related JP6723217B2 (ja) | 2014-07-16 | 2015-07-16 | Ｐｄｅ４阻害剤としての新規２，５−置換ピリミジン |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9546158B2 (enExample) |
| EP (2) | EP3169679A1 (enExample) |
| JP (1) | JP6723217B2 (enExample) |
| KR (1) | KR20170032421A (enExample) |
| CN (1) | CN106660996B (enExample) |
| AR (1) | AR101198A1 (enExample) |
| AU (1) | AU2015291475B2 (enExample) |
| BR (1) | BR112017000830A2 (enExample) |
| CA (1) | CA2955053A1 (enExample) |
| CL (1) | CL2017000106A1 (enExample) |
| CO (1) | CO2017001506A2 (enExample) |
| EA (1) | EA201790206A1 (enExample) |
| EC (1) | ECSP17010481A (enExample) |
| IL (1) | IL250026A0 (enExample) |
| MX (1) | MX366839B (enExample) |
| PE (1) | PE20170251A1 (enExample) |
| TW (1) | TW201613896A (enExample) |
| WO (1) | WO2016008590A1 (enExample) |
| ZA (1) | ZA201701131B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR101198A1 (es) | 2014-07-16 | 2016-11-30 | Gruenenthal Gmbh | Pirimidinas 2,5-sustituidas como inhibidores de pde4b |
| AR101196A1 (es) * | 2014-07-16 | 2016-11-30 | Gruenenthal Gmbh | Compuestos de pirimidina sustituidos |
| US11963823B2 (en) | 2016-10-03 | 2024-04-23 | Koninklijke Philips N.V. | Radiopaque arrangement of electronic components in intra-cardiac echocardiography (ICE) catheter |
| CN108570052A (zh) * | 2017-03-13 | 2018-09-25 | 中国科学院上海药物研究所 | 五元杂环并吡嗪化合物、制备方法、中间体、组合和应用 |
| WO2018234353A1 (en) | 2017-06-20 | 2018-12-27 | Grünenthal GmbH | Novel substituted indole and indazole compounds as phosphodiesterase inhibitors |
| WO2018234354A1 (en) | 2017-06-20 | 2018-12-27 | Grünenthal GmbH | Novel substituted 3-indole and 3-indazole compounds as phosphodiesterase inhibitors |
| SG11202104078PA (en) * | 2018-10-25 | 2021-05-28 | Merck Patent Gmbh | 5-azaindazole derivatives as adenosine receptor antagonists |
| CN110156785B (zh) * | 2019-04-15 | 2020-08-28 | 浙江大学 | 吲唑类化合物及其制备方法和应用 |
| US20240066027A1 (en) * | 2020-12-03 | 2024-02-29 | Domain Therapeutics | Novel par-2 inhibitors |
| CN115108992B (zh) * | 2022-06-29 | 2024-05-31 | 浙江手心制药有限公司 | 6-氯-2-甲基-2h-吲唑-5-胺的制备方法 |
| CN116836162B (zh) * | 2023-05-24 | 2025-09-05 | 南方医科大学 | 吡唑[4,3-c]吡啶类化合物或其药学上可接受的盐及其应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3818830A1 (de) | 1988-06-03 | 1989-12-14 | Boehringer Mannheim Gmbh | Bicyclische carboxamide, verfahren zu ihrer herstellung, deren vorstufen, und diese verbindungen enthaltende arzneimittel |
| US5712298A (en) | 1993-07-02 | 1998-01-27 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
| JP2000198734A (ja) | 1998-12-30 | 2000-07-18 | Pfizer Inc | 胃運動性減弱および関連疾患の治療のための運動性増強薬 |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| US7087597B1 (en) * | 1999-10-12 | 2006-08-08 | Takeda Pharmaceutical Company Limited | Pyrimidine 5-carboxamide compounds, process for producing the same and use thereof |
| JP2001233875A (ja) * | 1999-10-12 | 2001-08-28 | Takeda Chem Ind Ltd | ピリミジン−５−カルボキサミド化合物、その製造法およびその用途 |
| US6436965B1 (en) | 2000-03-02 | 2002-08-20 | Merck Frosst Canada & Co. | PDE IV inhibiting amides, compositions and methods of treatment |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| DE10163991A1 (de) | 2001-12-24 | 2003-07-03 | Merck Patent Gmbh | Pyrrolo-pyrimidine |
| EP2532650A3 (en) | 2004-06-24 | 2013-11-06 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| US20060293343A1 (en) | 2005-05-18 | 2006-12-28 | Asahi Kasei Pharma Corporation | Pyrimidine derivatives |
| CN101801971A (zh) | 2005-09-30 | 2010-08-11 | 沃泰克斯药物股份有限公司 | 可用作janus激酶抑制剂的脱氮嘌呤 |
| WO2007083182A2 (en) * | 2006-01-19 | 2007-07-26 | Orchid Research Laboratories Limited | Novel heterocycles |
| US7863446B2 (en) | 2006-01-19 | 2011-01-04 | Orchid Research Laboratories Limited | Heterocycles |
| EP1958947A1 (en) | 2007-02-15 | 2008-08-20 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type 4 |
| TW201512189A (zh) | 2013-04-16 | 2015-04-01 | Gruenenthal Chemie | 新型被取代之嘧啶縮合化合物 |
| AR101198A1 (es) | 2014-07-16 | 2016-11-30 | Gruenenthal Gmbh | Pirimidinas 2,5-sustituidas como inhibidores de pde4b |
| AR101196A1 (es) * | 2014-07-16 | 2016-11-30 | Gruenenthal Gmbh | Compuestos de pirimidina sustituidos |
| AR101197A1 (es) * | 2014-07-16 | 2016-11-30 | Gruenenthal Gmbh | Pirimidinas 2,5-sustituidas |
-
2015
- 2015-07-14 AR ARP150102233A patent/AR101198A1/es unknown
- 2015-07-15 US US14/800,252 patent/US9546158B2/en not_active Expired - Fee Related
- 2015-07-16 CN CN201580038259.8A patent/CN106660996B/zh not_active Expired - Fee Related
- 2015-07-16 MX MX2017000521A patent/MX366839B/es active IP Right Grant
- 2015-07-16 EP EP15739175.6A patent/EP3169679A1/en not_active Withdrawn
- 2015-07-16 AU AU2015291475A patent/AU2015291475B2/en not_active Ceased
- 2015-07-16 TW TW104123028A patent/TW201613896A/zh unknown
- 2015-07-16 EP EP18182049.9A patent/EP3415510A1/en not_active Withdrawn
- 2015-07-16 BR BR112017000830A patent/BR112017000830A2/pt not_active Application Discontinuation
- 2015-07-16 EA EA201790206A patent/EA201790206A1/ru unknown
- 2015-07-16 KR KR1020177004412A patent/KR20170032421A/ko not_active Withdrawn
- 2015-07-16 PE PE2017000066A patent/PE20170251A1/es not_active Application Discontinuation
- 2015-07-16 JP JP2017502119A patent/JP6723217B2/ja not_active Expired - Fee Related
- 2015-07-16 WO PCT/EP2015/001473 patent/WO2016008590A1/en not_active Ceased
- 2015-07-16 CA CA2955053A patent/CA2955053A1/en not_active Abandoned
-
2016
- 2016-11-17 US US15/354,424 patent/US10391099B2/en not_active Expired - Fee Related
-
2017
- 2017-01-10 IL IL250026A patent/IL250026A0/en unknown
- 2017-01-13 CL CL2017000106A patent/CL2017000106A1/es unknown
- 2017-02-15 ZA ZA2017/01131A patent/ZA201701131B/en unknown
- 2017-02-15 CO CONC2017/0001506A patent/CO2017001506A2/es unknown
- 2017-02-16 EC ECIEPI201710481A patent/ECSP17010481A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017520598A5 (enExample) | ||
| JP2017520600A5 (enExample) | ||
| JP2012515724A5 (enExample) | ||
| RU2454405C2 (ru) | Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина | |
| MX2024004790A (es) | Esteroides neuroactivos y sus metodos de uso. | |
| HRP20211918T1 (hr) | Triazol n-vezane karbamoil cikloheksil kiseline kao lpa antagonisti | |
| JP2014525425A5 (enExample) | ||
| NZ724602A (en) | Ror-gamma modulators and uses thereof | |
| JP2018516904A5 (enExample) | ||
| PH12020551304A1 (en) | Novel crystalline forms | |
| RU2019142795A (ru) | Производное n-(азаарил)циклолактам-1-карбоксамида, метод его получения и его применение | |
| RU2005137403A (ru) | Новые замещенные 3-сера-индолы | |
| RU2009140465A (ru) | Имидазохинолины с иммуномодулирующими свойствами | |
| JP2010523653A5 (enExample) | ||
| RU2004111979A (ru) | Производные 1н-имидазола, обладающие св1-агонистической, частичной св1-агонистической или св1-антагонистической активностью | |
| TW200738682A (en) | Isoquinoline derivatives | |
| JP2008515992A5 (enExample) | ||
| JP2012505891A5 (enExample) | ||
| JP2021500403A5 (enExample) | ||
| RU2003105885A (ru) | Ингибиторы клеточной адгезии, опосредованной альфа 4-интегринами | |
| JP2009539848A5 (enExample) | ||
| JP2011527666A5 (enExample) | ||
| JP2009510097A5 (enExample) | ||
| HRP20191734T1 (hr) | Pirimidinski derivati korisni kao selektivni jak3 i/ili jak1 inhibitori | |
| JP2019510801A5 (enExample) |